Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase

Diabetes Technology and Therapeutics

Volumn 14, Issue 3, 2012, Pages 218-224

  Hompesch, Marcus ^a   Muchmore, Douglas B ^b   Morrow, Linda ^a   Ludington, Elizabeth ^b,c   Vaughn, Daniel E ^b  

^a Profil Institute for Clinical Research   (United States)

^b Halozyme Therapeutics Inc   (United States)

^c Synteract Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN LISPRO; RECOMBINANT HYALURONIDASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOOD INTAKE; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INSULIN BLOOD LEVEL; MALE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPTIMAL DRUG DOSE; PHASE 2 CLINICAL TRIAL; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL QUALITY MANAGEMENT; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYALURONOGLUCOSAMINIDASE; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN LISPRO; INSULIN, REGULAR, HUMAN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84857833056     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0117     Document Type: Article

References (31)

1. 1c. Diabetes Care 2003;26:881-885. (Pubitemid 36929359)
2. Davidson J: Should postprandial glucose be measured and treated to a particular target? Yes. Diabetes Care 2003;26: 1919-1921. (Pubitemid 36929144)
3. Woerle HJ, Neumann C, Zschau S, Tenner S, Irsigler A, Schirra J, Gerich JE, Göke B: Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 2007;77:280-285. (Pubitemid 46670411)
4. American Diabetes Association: Standards of medical care in diabetes-2010. Diabetes Care 2010;33(Suppl 1):S11-S61.
5. IDF Clinical Guidelines Task Force: Global guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23:579-593.
6. American Association of Clinical Endocrinologists: AACE medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(Suppl):2-68.
7. Riddle M, Rosenstock J, Gerich J: The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086. (Pubitemid 37339502)
8. Holman R, Farmer A, Davies M, Levy J, Darbyshire J, Keenan J, Paul S: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;363:1737-1747.
9. DeWitt DE, Hirsch IB: Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003; 289:2254-264. (Pubitemid 37430194)
10. Brange J, Ribel U, Hansen J, Dodson FG, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Sørensen AR, Voigt HO: Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988; 333:679-682.
11. Becker RH, Frick AD: Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47:7-20. (Pubitemid 350260885)
12. Soeborg T, Rasmussen CH, Mosekilde E, Colding-Jorgensen M: Absorption kinetics of insulin after subcutaneous administration. Eur J Pharm Sci 2009;36:78-90.
13. Hirsch IB: Insulin analogues. N Engl J Med 2005;352: 174-183. (Pubitemid 40096614)
14. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR: [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994;43:396-402. (Pubitemid 24064246)
15. Lindholm A, McEwen J, Riis AP: Improved postprandial glycemic control with insulin aspart. A randomized doubleblind cross-over trial in type 1 diabetes. Diabetes Care 1999; 22:801-805. (Pubitemid 29220783)
16. Davis M: The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges. Int J Obes Relat Metab Disord 2004;28(Suppl 2):S14-S22.
17. Roper Global Diabetes Program: U.S. Diabetes Patient Market Study. Blue Bell, PA: GfK Healthcare, 2008.
18. National Center for Health Statistics, Centers for Disease Control and Prevention: NHANES 2007-2008. Diabetes Questionnaire. www.cdc.gov/nchs/nhanes/ nhanes2007-2008/quex07-08.htm (accessed May 27, 2010).
19. Aukland K, Reed RK: Interstitial-lymphatic mechanisms in the control of extracellular fluid volume. Physiol Rev 1993; 73:1-78. (Pubitemid 23065433)
20. Bookbinder LH, Hofer A, Haller MF, Zepeda ML, Keller GA, Lim JE, Edgington TS, Shepard HM, Patton JS, Frost GI: A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006;114: 230-241. (Pubitemid 44291844)
21. Frost GI: Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4:427-440. (Pubitemid 47249140)
22. Supersaxo A, Hein WR, Steffan H: Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990;7:167-169. (Pubitemid 20208069)
23. Hechter O: Studies on spreading factors: I. The importance of mechanical factors in hyaluronidase action in skin. J Exp Med 1947;85:77-97.
24. Holborow EJ, Keech MK: Hyaluronidase skin spreading effect: an analysis of repeated measurements. Br Med J 1951;2:1173-1178.
25. National Academy of Sciences, National Research Council: Drug efficacy study implementation review of hyaluronidase. Fed Register 1970;35(185):14800- 14801.
26. HYLENEX recombinant-(hyaluronidase human injection) [U.S. package insert]. Baxter Healthcare Corporation and Halozyme Therapeutics, Inc., 2009. www.hylenex.com/pdf/prescribe.pdf (accessed May 27, 2010).
27. Thomas JR, Yocum RC, HallerMF, von Gunten CF: Assessing the role of human recombinant hyaluronidase in gravitydriven subcutaneous hydration: the INFUSE-LR study. J Palliative Med 2007;10:1312-1320. (Pubitemid 350308641)
28. Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP, Frost GI: Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 2009;11: 345-352.
29. Muchmore DB, Vaughn DE: Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Technol 2010;4:419-428.
30. Hompesch M, Muchmore DB, Morrow L, Vaughn DE: Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care 2011;34:666-668.
31. Howey D, Bowsher R, Brunelle R, Rowe H, Santa P, Downing-Shelton J, Woodworth J: [Lys(B28), Pro(B29)]-human insulin: effect of injection time on postprandial glycemia. Clin Pharmacol Ther 1995;58:459-469.